Lori Berk

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

Sant P. Chawla, Arthur P. Staddon, Laurence H. Baker et al. · Journal of Clinical Oncology · 2011 · 247 citations · Full text

Medicine, Oncology, Pharmacology +16

Cancer-specific chromosome alterations in the constitutive fragile region <i>FRA3</i> B

Koshi Mimori, Teresa Druck, Hiroshi Inoue et al. · Proceedings of the National Academy of Sciences · 1999 · 124 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

Victor M. Rivera, Rachel M. Squillace, David F. Miller et al. · Molecular Cancer Therapeutics · 2011 · 105 citations · Full text

Medicine, Oncology, Pharmacology +15

A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

Christine Hartford, Apurva A. Desai, Linda Janisch et al. · Clinical Cancer Research · 2009 · 88 citations · Full text

Medicine, Oncology, Pharmacology +14

Sequence conservation at human and mouse orthologous common fragile regions, <i>FRA3B</i> / <i>FHIT</i> and <i>Fra14A2</i> / <i>Fhit</i>

Takeshi Shiraishi, Teresa Druck, Koshi Mimori et al. · Proceedings of the National Academy of Sciences · 2001 · 69 citations · Full text

Life Sciences, Genetics, Molecular Biology +13